Summers, J., Cohen, M. H., Keegan, P. & Pazdur, R. FDA Drug Approval Summary: Bevacizumab plus Interferon for Advanced Renal Cell Carcinoma. Oncologist 15, 104–111 (2010).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Atkins, M. B. et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993. J. Clin. Oncol. 17, 2105–2116 (1999).

Article  CAS  PubMed  Google Scholar 

Hodi, F. S. et al. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma. N. Engl. J. Med. 363, 711–723 (2010).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Robert, C. et al. Pembrolizumab versus ipilimumab in advanced melanoma. N. Engl. J. Med. 372, 2521–2532 (2015).

Article  CAS  PubMed  Google Scholar 

Powles, T. et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet 391, 748–757 (2018).

Article  CAS  PubMed  Google Scholar 

Vaddepally, R. K., Kharel, P., Pandey, R., Garje, R. & Chandra, A. B. Review of indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence. Cancers (Basel) 12, 738 (2020).

Article  CAS  PubMed  Google Scholar 

Kasherman, L., Ahrari, S. & Lheureux, S. Dostarlimab in the treatment of recurrent or primary advanced endometrial cancer. Futur. Oncol. 17, 877–892 (2021).

Article  CAS  Google Scholar 

Jardim, D., de Melo Gagliato, D., Giles, F. & Kurzrock, R. Analysis of Drug Development Paradigms for Immune Checkpoint Inhibitors. Clin. Cancer Res. 24, 1785–1794 (2018).

Article  CAS  PubMed  Google Scholar 

Garon, E. B. et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N. Engl. J. Med. 372, 2018–2028 (2015).

Article  PubMed  Google Scholar 

Reck, M. et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N. Engl. J. Med. 375, 1823–1833 (2016).

Article  CAS  PubMed  Google Scholar 

Patel, S. P. & Kurzrock, R. PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol. Cancer Ther. 14, 847–856 (2015).

Article  CAS  PubMed  Google Scholar 

Thorsson, V. et al. The Immune Landscape of Cancer. Immunity 48, 812–830.e14 (2018).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Litchfield, K. et al. Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition. Cell 184, 596 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

André, T. et al. Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer. N. Engl. J. Med. 383, 2207–2218 (2020).

Article  PubMed  Google Scholar 

Goodman, A. M. et al. Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers. Mol. Cancer Ther. 16, 2598–2608 (2017).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jardim, D. L., Goodman, A., de Melo Gagliato, D. & Kurzrock, R. The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker. Cancer Cell 39, 154–173 (2021).

Article  CAS  PubMed  Google Scholar 

Subbiah, V., Solit, D. B., Chan, T. A. & Kurzrock, R. The FDA approval of pembrolizumab for adult and pediatric patients with tumor mutational burden (TMB) ≥10: a decision centered on empowering patients and their physicians. Ann. Oncol. 31, 1115–1118 (2020).

Article  CAS  PubMed  Google Scholar 

Okamura, R. et al. ARID1A alterations function as a biomarker for longer progression-free survival after anti-PD-1/PD-L1 immunotherapy. J. Immunother. Cancer 8, e000438 (2020).

Article  PubMed  PubMed Central  Google Scholar 

Pham, T. V. et al. Role of ultraviolet mutational signature versus tumor mutation burden in predicting response to immunotherapy. Mol. Oncol. 14, 1680–1694 (2020).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Boichard, A. et al. APOBEC-related mutagenesis and neo-peptide hydrophobicity: implications for response to immunotherapy. Oncoimmunology 8, 1550341 (2019).

Article  PubMed  Google Scholar 

Boichard, A., Tsigelny, I. F. & Kurzrock, R. High expression of PD-1 ligands is associated with kataegis mutational signature and APOBEC3 alterations. Oncoimmunology 6, e1284719 (2017).

Article  PubMed  PubMed Central  Google Scholar 

Ganesh, K. et al. Immunotherapy in colorectal cancer: rationale, challenges and potential. Nat. Rev. Gastroenterol. Hepatol. 16, 361–375 (2019).

Article  PubMed  PubMed Central  Google Scholar 

Horn, L. et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N. Engl. J. Med. 379, 2220–2229 (2018).

Article  CAS  PubMed  Google Scholar 

Gutzmer, R. et al. Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 395, 1835–1844 (2020).

Article  CAS  PubMed  Google Scholar 

Baas, P. et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet 397, 375–386 (2021).

Article  CAS  PubMed  Google Scholar 

Seledtsov, V., Goncharov, A. & Seledtsova, G. Clinically feasible approaches to potentiating cancer cell-based immunotherapies. Hum. Vaccin. Immunother. 11, 851–869 (2015).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Westcott, P. M. K. et al. Low neoantigen expression and poor T-cell priming underlie early immune escape in colorectal cancer. Nat. Cancer 2, 1071 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kato, S. et al. Expression of TIM3/VISTA checkpoints and the CD68 macrophage-associated marker correlates with anti-PD1/PDL1 resistance: implications of immunogram heterogeneity. Oncoimmunology 9, 1708065 (2020).

Article  PubMed  PubMed Central  Google Scholar 

Vano, Y. A. et al. Nivolumab, nivolumab-ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial. Lancet Oncol. 23, 612–624 (2022).

Article  CAS  PubMed  Google Scholar 

Ward, J. H. Hierarchical Grouping to Optimize an Objective Function. J. Am. Stat. Assoc. 58, 236–244 (1963).

Article  Google Scholar 

Derks, S. et al. Characterizing diversity in the tumor-immune microenvironment of distinct subclasses of gastroesophageal adenocarcinomas. Ann. Oncol. 31, 1011–1020 (2020).

Article  CAS  PubMed  Google Scholar 

Fuchs, C. S. et al. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: Phase 2 clinical KEYNOTE-059 trial. JAMA Oncol. 4, e180013 (2018).

Article  PubMed  PubMed Central  Google Scholar 

Wang, L., Zhu, B., Zhang, M. & Wang, X. Roles of immune microenvironment heterogeneity in therapy-associated biomarkers in lung cancer. Semin Cell Dev. Biol. 64, 90–97 (2017).

Article  CAS  PubMed  Google Scholar 

Gao, Y. et al. Heterogeneity of immune microenvironment in ovarian cancer and its clinical significance: a retrospective study. Oncoimmunology 9, 1760067 (2020).

Article  PubMed  PubMed Central  Google Scholar 

Kim, S. T. et al. Tumor-infiltrating lymphocytes, tumor characteristics, and recurrence in patients with early breast cancer. Am. J. Clin. Oncol. Cancer Clin. Trials 36, 224–231 (2013).

CAS  Google Scholar 

Chen, Y. P. et al. Unraveling tumour microenvironment heterogeneity in nasopharyngeal carcinoma identifies biologically distinct immune subtypes predicting prognosis and immunotherapy responses. Mol. Cancer 20, 14 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cullen, S. P., Brunet, M. & Martin, S. J. Granzymes in cancer and immunity. Cell Death Differ. 17, 616–623 (2010).

Article  CAS